The Revival of Most-Favored-Nation Pricing: What Pharma Needs to Know

Join us for a webinar exploring the evolving antitrust landscape as it intersects with drug pricing policy and regulation under the current administration. Reviving the “most-favored-nation” drug pricing principle of the prior Trump administration, this administration is leveraging antitrust tools to address high pharmaceutical costs, signaling a shift toward increased regulatory scrutiny of market power and pricing disparities. Our attorneys will cover the latest executive orders and proposed agency actions, potential implications for pharmaceutical companies and the broader healthcare industry, and how to navigate this changing regulatory environment.  

Register Here